Abstract: Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an adenoviral vector with a genetically modified fiber incorporating a Lyp-1 peptide motif and at least one CD122/CD132 agonist and/or an immune checkpoint inhibitor.

Abstract: The disclosed subject matter provides methods and materials relating to viral vectors, such as adenoviral vectors, that effectively target cancer cells and that express a protein that specifically binds to Transforming Growth Factor-?.

Abstract: The present invention relates to methods and compositions for treating thrombotic diseases using gene delivery technologies. In one embodiment, a therapeutically effective amount of a TM gene product is expressed in a TM-deficient mammal using a viral or non viral vector. In another embodiment, the vector-mediated in vivo TM gene expression is used for the treatment of atherosclerotic cardiovascular disease, pulmonary hypertension, acute inflammatory diseases, end-stage renal failure disease, or Alzheimer disease. In yet another embodiment, a vector carrying a TM inhibitory polynucleotide in which the vector is introduced into a mammal to reduce the TM activity or TM gene expression in vivo.

Abstract: The present invention provides an adenoviral-mediated method of transfection with nucleic acids which can be augmented through incubation of the nucleic acids with cationic agents. Specifically, the present inventive method of introducing a nucleic acid into a eukaryotic cell comprises contacting the cell with, in any order or simultaneously, the nucleic acid and an adenovirus, wherein the nucleic acid is not bound to any molecule capable of effecting its entry into the cell. The cell is preferably additionally contacted with a cationic agent, such as a monocationic or polycationic liposome, such that the nucleic acid is not bound to any molecule capable of effecting its entry into the cell other than, optionally, the cationic agent.